Krystal Biotech logo

Krystal BiotechNASDAQ: KRYS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 September 2017

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$5.07 B
-17%vs. 3y high
89%vs. sector
-97%vs. 3y high
76%vs. sector
-17%vs. 3y high
85%vs. sector
-92%vs. 3y high
88%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:35:08 GMT
$176.39+$3.86(+2.24%)

Dividend

No data over the past 3 years
$70.28 M$82.94 M
$70.28 M$15.57 M

Analysts recommendations

Institutional Ownership

KRYS Latest News

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
globenewswire.com28 October 2024 Sentiment: POSITIVE

PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets.

All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy
zacks.com18 October 2024 Sentiment: POSITIVE

Krystal Biotech (KRYS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
https://seekingalpha.com/article/4726720-krystal-biotech-q4-catalysts-expected-with-vyjuvek-revenue-growth-pressing-on14 October 2024 Sentiment: POSITIVE

The company anticipates significant Q4 2024 data releases for KB707 in solid tumors and KB408 in AATD lung disease, potentially boosting shareholder value. Jeune Therapeutics, a subsidiary, shows promise in aesthetics with positive phase 1 data, changing the treatment paradigm in the aesthetics market space. VYJUVEK, approved for DEB, saw a 55.3% revenue increase in Q2 2024, with potential European expansion pending MAA approval.

Surging Earnings Estimates Signal Upside for Krystal Biotech (KRYS) Stock
zacks.com03 September 2024 Sentiment: POSITIVE

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
zacks.com30 August 2024 Sentiment: POSITIVE

KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.

Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript
seekingalpha.com09 August 2024 Sentiment: POSITIVE

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Stéphane Paquette - Vice President, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - Senior Vice President, Patient Access, Analytics and Operations Christine Wilson - Senior Vice President and Head, U.S. Sales and Marketing Kate Romano - Chief Accounting Officer Conference Call Participants Alec Stranahan - Bank of America Ritu Baral - TD Cowen Andrea Tan - Goldman Sachs John Boyle - William Blair Yigal Nochomovitz - Citi Gavin Clark Gartner - Evercore ISI Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Securities Operator Thank you for standing by. And welcome to Krystal Biotech's Second-Quarter 2024 Earnings Conference Call.

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates
zacks.com05 August 2024 Sentiment: POSITIVE

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to loss of $1.25 per share a year ago.

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
seekingalpha.com30 July 2024 Sentiment: NEUTRAL

Krystal Biotech's Q1 2024 revenue increased to $45.25 million but fell short of analyst expectations of $47.37 million. Analysts expect Q2 earnings to be $65.49 million. Vyjuvek's patient adherence rate dropped slightly to 91% in Q1 from 96% in the previous quarter. Krystal's pipeline, beyond dermatological and aesthetic pursuits, is pretty speculative and pursuing highly contested indications.

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
globenewswire.com26 July 2024 Sentiment: POSITIVE

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U.S. markets.

Krystal Biotech (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
zacks.com18 July 2024 Sentiment: POSITIVE

Krystal Biotech (KRYS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

  • 1(current)
  • 2

What type of business is Krystal Biotech?

Krystal Biotech is a manufacturer of gene therapy drugs, engaged in their clinical development and striving to create and bring to market modern drugs for patients with skin diseases. The company has developed and patented a gene therapy platform that allows for the development of ready-to-use treatments for skin diseases that cannot be cured by known methods. Krystal Biotech, Inc. was founded in 2015, with its headquarters located in Pittsburgh, Pennsylvania.

What sector is Krystal Biotech in?

Krystal Biotech is in the Healthcare sector

What industry is Krystal Biotech in?

Krystal Biotech is in the Biotechnology industry

What country is Krystal Biotech from?

Krystal Biotech is headquartered in United States

When did Krystal Biotech go public?

Krystal Biotech initial public offering (IPO) was on 20 September 2017

What is Krystal Biotech website?

https://www.krystalbio.com

Is Krystal Biotech in the S&P 500?

No, Krystal Biotech is not included in the S&P 500 index

Is Krystal Biotech in the NASDAQ 100?

No, Krystal Biotech is not included in the NASDAQ 100 index

Is Krystal Biotech in the Dow Jones?

No, Krystal Biotech is not included in the Dow Jones index

When was Krystal Biotech the previous earnings report?

No data

When does Krystal Biotech earnings report?

The next expected earnings date for Krystal Biotech is 06 November 2024